期刊
JOURNAL OF PAIN
卷 16, 期 12, 页码 1221-1232出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jpain.2015.07.009
关键词
Cannabis; chronic pain; neuropathy; painful; polyneuropathy; meta-analysis; meta-analysis of individual patient data; Bayesian analysis; human immunodeficiency virus
资金
- National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), through CTSA [UL1TR000086, TL1RR000087, KL2TR000088]
- Center for Drug Evaluation and Research (CDER) [R01-AT005824]
- National Center for Complementary and Alternative Medicine (NCCAM) [5R01AT5824]
- University of California Center for Medicinal Cannabis Research
- NIH [5-MO1-RR00083]
Chronic neuropathic pain, the most frequent condition affecting the peripheral nervous system, remains underdiagnosed and difficult to treat. Inhaled cannabis may alleviate chronic neuropathic pain. Our objective was to synthesize the evidence on the use of inhaled cannabis for chronic neuropathic pain. We performed a systematic review and a meta-analysis of individual patient data. We registered our protocol with PROSPERO CRD42011001182. We searched in Cochrane Central, PubMed, EMBASE, and AMED. We considered all randomized controlled trials investigating chronic painful neuropathy and comparing inhaled cannabis with placebo. We pooled treatment effects following a hierarchical random-effects Bayesian responder model for the population-averaged subject-specific effect. Our evidence synthesis of individual patient data from 178 participants with 405 observed responses in 5 randomized controlled trials following patients for days to weeks provides evidence that inhaled cannabis results in short-term reductions in chronic neuropathic pain for 1 in every 5 to 6 patients treated (number needed to treat = 5.6 with a Bayesian 95% credible interval ranging between 3.4 and 14). Our inferences were insensitive to model assumptions, priors, and parameter choices. We caution that the small number of studies and participants, the short follow-up, shortcomings in allocation concealment, and considerable attrition limit the conclusions that can be drawn from the review. The Bayes factor is 332, corresponding to a posterior probability of effect of 99.7%. Perspective: This novel Bayesian meta-analysis of individual patient data from 5 randomized trials suggests that inhaled cannabis may provide short-term relief for 1 in 5 to 6 patients with neuropathic pain. Pragmatic trials are needed to evaluate the long-term benefits and risks of this treatment. (C) 2015 by the American Pain Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据